Drug Topics
MAY 28, 2024
A recent study found that if community pharmacists were utilized to treat common conditions, it could result in significant cost-savings for the health care system.
STAT
MAY 28, 2024
When Yilai Shu was training to be an otolaryngologist in Shanghai, in the mid 2000s, he often met parents with congenitally deaf kids. “They always asked me, ‘Do you have any drugs to treat our kids?’ said Shu, who is hearing and a professor at Fudan University in China. “That’s what really inspired me to think about developing a drug.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
MAY 28, 2024
Research exploring the growing role of artificial intelligence (AI) in health care sheds a light on the potential of the technology to improve skin cancer detection and awareness among patients and health care professionals.
STAT
MAY 28, 2024
Merus said Tuesday that the combination of its experimental drug petosemtamab with the checkpoint inhibitor Keytruda shrank tumors in 62% of patients with head and neck cancer, according to an interim analysis of an ongoing mid-stage clinical trial. The new efficacy results, derived from a larger number of patients, look similar to an initial disclosure made last week that triggered a 36% increase in Merus’ stock price.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmacy Times
MAY 28, 2024
The study estimates that over 40% of academic pulmonary and allergy providers have not adopted the Single Maintenance and Reliever Therapy combination method in their practices.
STAT
MAY 28, 2024
Heat waves are becoming more frequent and more intense, posing more of a health risk around the world. High temperatures can be deadly, and are especially dangerous for those with cardiovascular and chronic disease — but they begin affecting human lives even before birth. Several studies have identified an increased risk of preterm delivery and stillbirth after heat exposure around the world.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
MAY 28, 2024
LAS VEGAS — Mark Parrino, the longtime leader of the U.S. methadone clinic industry, kicked off his organization’s conference here last week with a simple message: Allowing addiction doctors to prescribe the medication directly to their patients is “not a good idea.” It was a revealing warning both in timing and tone.
Pharmacy Times
MAY 28, 2024
Under the proposal, specific drugs would be prohibited
Fierce Pharma
MAY 28, 2024
A recently announced $900 million restructuring drive is already making waves at Takeda, wi | From early July to March 2025, the Japanese drugmaker will cut 495 staffers at its Cambridge location and 146 in Lexington, Massachusetts. Takeda is the largest life sciences employer in the state.
STAT
MAY 28, 2024
Gen Z has made captioning cool. Captions are now widely available in social media, entertainment channels, and web conferencing platforms, including YouTube, Hulu, and Zoom. Yet, there is one extremely important place where captions are not regularly available: telehealth visits. This disproportionately affects people with hearing loss. A friend of ours with hearing loss, whom we will call Cheryl, recently told us about her disappointing telehealth visit.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacy Times
MAY 28, 2024
Added data from the SELECT trial helps to increase confidence in safety and efficacy of semaglutide, a glucagon-like peptide 1 medication.
STAT
MAY 28, 2024
An experimental drug from Insmed Incorporated successfully reduced lung problems among patients with an airway disease in a closely watched Phase 3 trial, sending the company’s share price soaring early Tuesday. The drug, brensocatib, reduced so-called pulmonary exacerbations by roughly 20% versus placebo in patients with bronchiectasis, hitting the trial’s primary endpoint.
Fierce Pharma
MAY 28, 2024
A data breach at drug distributor Cencora has left sensitive information vulnerable, with patients on medicines from a dozen drugmakers potentially affected. | The potentially compromised data included patient information such as names and addresses, Cencora disclosed in letters to patients who may have been affected.
Fierce Healthcare
MAY 28, 2024
Hospital lobbies have signed onto a multi-sector letter of 230 industry associations and chambers of commerce urging the Federal Trade Commission to bump the effective date of its ban on employee n | The American Hospital Association and the Federation of American Hospitals are among 230 groups urging the regulator to put the final rule on hold pending legal challenges and "lack of Commission guidance on key pieces" of the ban.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
MAY 28, 2024
Although sun-protective measures have been increasing, the incidence of skin cancer has also increased, suggesting better targeted interventions and patient education are needed.
Fierce Healthcare
MAY 28, 2024
While health AI legislation remains distant, Senate wants to appropriate funds, spur action in committees and agencies ebeavins Tue, 05/28/2024 - 14:35
Pharmacy Times
MAY 28, 2024
The authors note further research on technological monitoring methods can help health care providers better optimize patient care and improve nonadherence and nonpersistence.
STAT
MAY 28, 2024
LONDON — Seeking to build up its pharma business, the Japanese conglomerate Asahi Kasei is moving to buy Swedish biotech Calliditas Therapeutics in a nearly $1.1 billion cash deal, the companies said Tuesday. The firm’s offer of $19.68 per share amounts to an 83% premium versus Calliditas’ closing price on a Swedish exchange Monday.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
MAY 28, 2024
The rise of AI is shaking up the healthcare industry. Learn how the MHRA is working to ensure the safe and effective use of AI in drugs and medical devices.
Fierce Pharma
MAY 28, 2024
Bolstered by a full FDA approval for its primary immunoglobulin A nephropathy (IgAN) treatment Tarpeyo, Calliditas has earned the attention of Japanese chemical giant Asahi Kasei. | Asahi Kasei has made a cash offer to acquire Calliditas in a deal worth 11.16 billion Swedish crowns ($1.06 billion), the companies announced Tuesday. Asahi’s bid represents a 74% premium to Calliditas' prior closing price.
pharmaphorum
MAY 28, 2024
NLRP3-focused biotech NodThera has named former Jazz Pharma and Sunesis executive Dan Swisher as its new CEO.
STAT
MAY 28, 2024
Good morning, everyone, and welcome to another working week. We hope the weekend respite — which was extended on this side of the pond thanks to a holiday — was relaxing and invigorating. Now, though, the time has come to resume the usual routines of online meetings, phone calls, and what-not. After all, the world continues to spin, although it remains a bit wobbly where we are after losing a Pharmalot ancestor, which explains our recent disappearance.
pharmaphorum
MAY 28, 2024
Shares in Insmed double as phase 3 trial sets up filings for brensocatib, aiming to become the first approved drug for bronchiectasis
Drug Topics
MAY 28, 2024
Don’t miss out on the latest pharmacy insights in the Drug Topics May issue.
Fierce Pharma
MAY 28, 2024
Since NS Pharma launched its Duchenne muscular dystrophy (DMD) drug Viltepso (viltolarsen) in 2020, sales have steadily
Drug Topics
MAY 28, 2024
Check out these top featured stories from Drug Topics in May 2024.
STAT
MAY 28, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hi, biotech friends. As we gear up for ASCO, we cogitate on some interesting questions. For instance: Gene therapy carries great potential to cure certain forms of congenital deafness, but does the community actually want that?
Pharmaceutical Commerce
MAY 28, 2024
Results from the CORE-001 clinical trial are expected to be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting.
Fierce Pharma
MAY 28, 2024
Novartis is eyeing an FDA filing for a second drug in immunoglobulin A nephropathy (IgAN), as the Swiss pharma goes all-in on the rare autoimmune kidney disease from three different angles. | Novartis is eyeing an FDA filing for a second drug in immunoglobulin A nephropathy (IgAN), as the Swiss pharma goes all-in on the rare autoimmune kidney disease from three different angles.
Pharmaceutical Commerce
MAY 28, 2024
Among its benefits, the fund will provide up to $8,000 in medication copayment or insurance premium assistance.
European Pharmaceutical Review
MAY 28, 2024
Researchers have defined the conditions to formulate novel polyelectrolyte complexes (PECs) based on a sustainable hemicellulose-rich lignosulphonate. Their findings suggest potential applications in drug delivery. Novel biomaterials based on PECs are being investigated in the industry as drug delivery systems, due to PECs being able to “to entrap drugs under mild conditions and control their release”.
Pharmaceutical Commerce
MAY 28, 2024
The latest news for pharma industry insiders.
STAT
MAY 28, 2024
The ASCO annual meeting is widely considered one of the largest and most prestigious cancer research conferences in the world. From May 31-June 4, more than 40,000 oncology professionals will gather in Chicago for an event featuring 200 professional sessions and the presentation of more than 5,000 abstracts. STAT will host a kickoff event May 31, featuring top experts in oncology, and will offer a live wrap-up broadcast on June 5.
Expert insights. Personalized for you.
211 
Let's personalize your content